Fig. 2: Antitumor efficacies of c4G12 in dogs with oral malignant melanoma. | npj Precision Oncology

Fig. 2: Antitumor efficacies of c4G12 in dogs with oral malignant melanoma.

From: PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

Fig. 2

a Representative tumor response in dogs with measurable disease. The dog (Pomeranian, male, 12-year-old, #10 in Supplementary Tables 2, 3) received c4G12 at a dose of 5 mg/kg every 2 weeks. Oral recurrent tumor (upper panel) and pulmonary metastatic lesions (lower panel) responded to treatment at week 7. b, c Representative tumor response in dogs with non-measurable disease. b The dog (Pekingese, castrated male, 8-year-old, #12) received c4G12 at a dose of 5 mg/kg every 2 weeks. Pulmonary metastatic lesions were confirmed at week 4. Subsequently, the lesions responded to treatment at week 12. c The dog (Beagle, spayed female, 11-year-old, #5) received c4G12 at a dose of 5 mg/kg every 2 weeks until week 12 and thereafter the dose was changed to 2 mg/kg. A metastatic lesion in the lung (upper panel) disappeared at week 6. In contrast, the other lesion (lower panel) showed slight increase in tumor size at week 6, followed by complete regression at week 18 (an immune-related pattern of response). Contrast-enhanced and matched transverse CT images are shown. Arrow heads indicate tumor lesions.

Back to article page